Balancing Medicare Costs: The Delay of the BALANCE Program for Weight-Loss Drugs
The Trump administration's proposed Medicare pilot program for GLP-1 weight-loss drugs aimed to address medication costs and improve seniors' healthcare outcomes. A 2025 study by the Cleveland Clinic Journal of Medicine highlights that 41.5% of U.S. adults aged 60 and older are affected by obesity, indicating the pilot's potential impact on senior health care.
Current regulations prevent Medicare from covering weight-loss medications directly. The proposed pilot, called the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) program, sought to circumvent this by allowing the Centers for Medicare & Medicaid Services (CMS) to directly negotiate with manufacturers of GLP-1 drugs. The program would have required insurers' participation, with beneficiaries accessing drugs at a reduced co-pay of $50.
Although Eli Lilly and Novo Nordisk had agreed last year to reduce drug prices in exchange for broader patient access, the program's continuation hinged on insurer engagement. However, CMS was unable to secure sufficient insurer participation by the deadline. Both CVS Health and UnitedHealth opted out, citing concerns over the program's structure and fiscal implications. In a recent statement, Bobby Hunter, CEO of government programs at UnitedHealth, acknowledged significant challenges within the proposed setup.
Under the agreements made, drug manufacturers had reduced the price of treatments to $245 for Medicare and Medicaid beneficiaries, intending for a monthly beneficiary payment of $50. The remaining cost was anticipated to be covered by insurers, leading to financial hesitancy. Although the five-year BALANCE program is delayed, a transitional plan will commence in July 2027. The bridge program will enable Medicare to cover certain weight-loss drugs, allowing eligible seniors to obtain medications like Wegovy and Zepbound for a co-pay of $50.
However, the bridge program operates independently of the Medicare Part D benefit, meaning the co-payments will not contribute towards the deductible or out-of-pocket limits. Additionally, low-income beneficiaries cannot utilize their subsidies for these medications, possibly posing a financial barrier. If beneficiaries require GLP-1 medications for additional health conditions such as diabetes, they must still use Medicare Part D, even if it results in higher costs than the bridge program’s offerings.
The full implementation of the BALANCE model, initially slated for July 2026, has been postponed to at least 2027, pending increased insurer participation. CMS has noted that additional time and data could enhance the program's eventual rollout. The current bridge program aims to maintain access to weight-loss medications for Medicare beneficiaries, albeit with some limitations. The broader BALANCE initiative remains dependent on fuller collaboration from insurers, reflecting ongoing challenges within this segment of healthcare coverage.